Please login to the form below

Not currently logged in
Email:
Password:

Sepracor's epilepsy drug cuts seizures

Sepracor has said its esclicarbazepine acetate drug causes a significant reduction in the frequency of seizures
Sepracor has said that results of its randomised, double-blind trials involving 1,049 patients show that compared to a placebo, patients given its esclicarbazepine acetate drug (in either 800mg or 1200mg doses) experience a significant reduction in the frequency of seizures.

The phase III trials involved patients, who despite being treated with epilepsy drugs, experienced four or more partial seizures per month. Over a 12-week period, patients receiving the 800mg dosage showed a 35.4 per cent relative reduction in seizure frequency. Patients receiving the 1200mg dose showed a 38.8 per cent reduction.

In an open-label follow up study lasting 52 weeks, patients who were given esclicarbazepine acetate showed statistically significant improvements in quality of life.

Esclicarbazepine acetate is designed to be used in combination with other anti-epileptic drugs. It is a sodium channel blocker that works by blocking electrical signals in the brain to reduce the frequency of partial-onset seizures.

19th June 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Six Degrees Medical Consulting

Partnering with top global pharmaceutical companies, we push the boundaries to create meaningful, impactful and lasting learning opportunities. We leverage...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics